{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:13:13Z","timestamp":1789413193750,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["JCYJ20220531093612027"],"award-info":[{"award-number":["JCYJ20220531093612027"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024B03J1249"],"award-info":[{"award-number":["2024B03J1249"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023A1515010123"],"award-info":[{"award-number":["2023A1515010123"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.redox.2024.103245","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:50:05Z","timestamp":1718715005000},"page":"103245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism"],"prefix":"10.1016","volume":"75","author":[{"given":"Mengqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-9152","authenticated-orcid":false,"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-7026","authenticated-orcid":false,"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.redox.2024.103245_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006-2016: an analysis of the global Burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.redox.2024.103245_bib4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.redox.2024.103245_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00003495-198427050-00002","article-title":"Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis","volume":"27","author":"Chaffman","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.redox.2024.103245_bib6","first-page":"279","article-title":"Gold complexes in the treatment of rheumatoid arthritis","volume":"41","author":"Messori","year":"2004","journal-title":"Met. Ions Biol. Syst."},{"key":"10.1016\/j.redox.2024.103245_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.redox.2015.12.004","article-title":"The thioredoxin system in breast cancer cell invasion and migration","volume":"8","author":"Bhatia","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/djy149","article-title":"Auranofin\/vitamin C: a novel drug combination targeting triple-negative breast cancer","volume":"111","author":"Hatem","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.redox.2024.103245_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ijc.32410","article-title":"Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer","volume":"146","author":"Raninga","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.redox.2024.103245_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.freeradbiomed.2006.12.021","article-title":"Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells","volume":"42","author":"Marzano","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2024.103245_bib11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3892\/ijo.2014.2579","article-title":"Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53","volume":"45","author":"Park","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/0008-5472.CAN-18-1938","article-title":"Inhibition of thioredoxin\/thioredoxin reductase induces Synthetic lethality in lung cancers with compromised glutathione homeostasis","volume":"79","author":"Yan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2024.103245_bib13","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-11-0736","article-title":"Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism","volume":"17","author":"Fath","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2024.103245_bib14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s10637-019-00750-2","article-title":"A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer","volume":"37","author":"Liu","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.redox.2024.103245_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/15384101.2015.1136038","article-title":"TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-small ka, Cyrillicbeta inhibition","volume":"15","author":"Raninga","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.redox.2024.103245_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fonc.2019.00128","article-title":"Targeting oxidative stress with auranofin or prima-1(met) to circumvent p53 or bax\/bak deficiency in myeloma cells","volume":"9","author":"Tessoulin","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101310","article-title":"Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma","volume":"28","author":"Sze","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/1878-0261.12476","article-title":"Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia","volume":"13","author":"Fidyt","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcp.2016.01.004","article-title":"Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis","volume":"105","author":"Hass","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.redox.2024.103245_bib20","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","article-title":"Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia","volume":"74","author":"Fiskus","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2024.103245_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-019-0259-8","article-title":"Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma","volume":"9","author":"Wang","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.redox.2024.103245_bib22","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2015-07-660365","article-title":"Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma","volume":"126","author":"Celegato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.redox.2024.103245_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.11.020","article-title":"Inhibition of thioredoxin-dependent H(2)O(2) removal sensitizes malignant B-cells to pharmacological ascorbate","volume":"21","author":"Graczyk-Jarzynka","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.exphem.2014.10.004","article-title":"Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach","volume":"43","author":"Kiebala","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.redox.2024.103245_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2009.07.023","article-title":"Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase","volume":"79","author":"Gandin","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.redox.2024.103245_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101153","article-title":"Peperomin E and its orally bioavailable analog induce oxidative stress-mediated apoptosis of acute myeloid leukemia progenitor cells by targeting thioredoxin reductase","volume":"24","author":"Wang","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2567.2007.02679.x","article-title":"Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3","volume":"122","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.redox.2024.103245_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5483\/BMBRep.2013.46.1.123","article-title":"Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells","volume":"46","author":"Kim","year":"2013","journal-title":"BMB Rep"},{"key":"10.1016\/j.redox.2024.103245_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2010.05.011","article-title":"The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity","volume":"35","author":"Nakaya","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.redox.2024.103245_bib30","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.4049\/jimmunol.164.11.5981","article-title":"Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase","volume":"164","author":"Jeon","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.redox.2024.103245_bib31","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1541-7786.MCR-13-0371-T","article-title":"PKCiota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis","volume":"11","author":"Wang","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.redox.2024.103245_bib32","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1158\/0008-5472.CAN-08-0438","article-title":"Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells","volume":"68","author":"Regala","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2024.103245_bib33","article-title":"A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.redox.2024.103245_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070931","article-title":"Synergy between auranofin and celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism","volume":"11","author":"Han","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.redox.2024.103245_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-017-0159-4","article-title":"Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis","volume":"9","author":"Hou","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.redox.2024.103245_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101652","article-title":"Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo","volume":"36","author":"Liu","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4149\/gpb_2016043","article-title":"Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species","volume":"36","author":"Hwang-Bo","year":"2017","journal-title":"Gen. Physiol. Biophys."},{"key":"10.1016\/j.redox.2024.103245_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910790","article-title":"Inhibition of mitochondrial metabolism leads to selective eradication of cells adapted to acidic microenvironment","volume":"22","author":"Konco\u0161ov\u00e1","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.redox.2024.103245_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2015.06.017","article-title":"Acute activation of oxidative pentose phosphate pathway as first-line response to oxidative stress in human skin cells","volume":"59","author":"Kuehne","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.redox.2024.103245_bib40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42255-023-00781-3","article-title":"The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells","volume":"5","author":"Talwar","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.redox.2024.103245_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12032-015-0526-x","article-title":"A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma","volume":"32","author":"Zhao","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.redox.2024.103245_bib42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.tiv.2006.01.012","article-title":"Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1)","volume":"20","author":"Omata","year":"2006","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.redox.2024.103245_bib43","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1073\/pnas.100114897","article-title":"Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol\/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence","volume":"97","author":"Zhong","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.redox.2024.103245_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2011.145","article-title":"K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis","volume":"22","author":"Hu","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.redox.2024.103245_bib45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ymthe.2022.12.011","article-title":"Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma","volume":"31","author":"Raninga","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.redox.2024.103245_bib46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cmet.2015.07.027","article-title":"Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis","volume":"22","author":"Gray","year":"2015","journal-title":"Cell Metabol."},{"key":"10.1016\/j.redox.2024.103245_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2016.06.005","article-title":"Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy","volume":"24","author":"Petersen","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.redox.2024.103245_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101780","article-title":"Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling","volume":"38","author":"Glorieux","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.redox.2024.103245_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194864","article-title":"Novel insights into redox-based mechanisms for auranofin-induced rapid cancer cell death","volume":"14","author":"Hatem","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.redox.2024.103245_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101491","article-title":"Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin","volume":"32","author":"Saei","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib52","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1038\/s41467-020-18324-9","article-title":"A role for annexin A2 in scaffolding the peroxiredoxin 2-STAT3 redox relay complex","volume":"11","author":"Talwar","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2024.103245_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00775-010-0624-3","article-title":"Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study","volume":"15","author":"Magherini","year":"2010","journal-title":"J Biol Inorg Chem"},{"key":"10.1016\/j.redox.2024.103245_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1039\/c2mt00083k","article-title":"Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds","volume":"4","author":"Guidi","year":"2012","journal-title":"Metallomics"},{"key":"10.1016\/j.redox.2024.103245_bib55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/164_2020_393","article-title":"Effects of mammalian thioredoxin reductase inhibitors","volume":"264","author":"Arn\u00e9r","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.redox.2024.103245_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001846","article-title":"Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells","volume":"3","author":"Anest\u00e5l","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2024.103245_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7444","article-title":"Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy","volume":"10","author":"Stafford","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.redox.2024.103245_bib58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/acsmedchemlett.7b00489","article-title":"Manumycin A is a potent inhibitor of mammalian thioredoxin reductase-1 (TrxR-1)","volume":"9","author":"Tuladhar","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.redox.2024.103245_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101646","article-title":"To inhibit TrxR1 is to inactivate STAT3-Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors","volume":"36","author":"Busker","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2024.103245_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nchembio.1695","article-title":"Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling","volume":"11","author":"Sobotta","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.redox.2024.103245_bib61","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.redox.2024.103245_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231724002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231724002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T11:44:00Z","timestamp":1724067840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231724002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":62,"alternative-id":["S2213231724002234"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2024.103245","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2024.103245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103245"}}